Search clinical trials for: Histone Deacetylase Inhibitors (HDACi)

Total 64232 results

National Cancer Institute (NCI)

Terminated

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
National Cancer Institute (NCI)

Completed

PXD101 in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Syndax Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

United States
National Cancer Institute (NCI)

Completed

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
National Center for Tumor Diseases, Heidelberg
Merck Sharp & Dohme LLC; University Hospital Heidelberg

Completed

Vorinostat in Children

Children With Relapsed Solid Tumor, Lymphoma or Leukemia

Germany
Ajai Chari
Novartis Pharmaceuticals

Completed

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Adult Solid Neoplasm

United States
Johann Wolfgang Goethe University Hospital

Unknown

Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (PANOBEST)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Alison Walker

Completed

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
St. Jude Children's Research Hospital

Terminated

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Acute Myeloid Leukemia | Acute Lymphoid Leukemia | Mixed Lineage Acute Leukemia

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Nodal Marginal Zone Lymphoma

United States
Holy Cross Hospital, Florida

Terminated

Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer (HCH003)

Non-Small-Cell Lung Carcinoma

United States
Eunice Kennedy Shriver National Institute of Child...
Washington University School of Medicine; Weill Medical College of Cornell...

Completed

Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1

Neimann-Pick Disease

United States
NYU Langone Health
Novartis

Completed

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Prostatic Neoplasms | Prostate Cancer

United States
Kanazawa University

Unknown

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer (VICTORY-J)

Non-Small-Cell Lung Carcinoma

Japan
Barretos Cancer Hospital

Completed

Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid (GAMA)

Head and Neck Squamous Cell Carcinoma

Brazil
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

Depression | Adult Glioblastoma | Recurrent Adult Brain Tumor

United States
Massachusetts General Hospital
National Comprehensive Cancer Network

Completed

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Terminated

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of California, Davis
Novartis Pharmaceuticals

Completed

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Solid Tumors | Non-Small Cell Lung Cancer (NSCLC)

United States
Memorial Sloan Kettering Cancer Center
Northwestern University; Merck Sharp & Dohme LLC; Weill Medical College of Cornell... and other collaborators

Completed

Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma | Hodgkin's Disease

United States
University Health Network, Toronto
AstraZeneca; Mirati Therapeutics Inc.

Withdrawn

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (PRIMED-001)

Squamous Cell Carcinoma, Head And Neck | Squamous Cell Carcinoma Mouth | Resectable Squamous Cell Carcinoma of Oral Cavity

Canada
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Leukemia | Myelodysplastic Syndrome

United States
Masonic Cancer Center, University of Minnesota

Terminated

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

United States
Masonic Cancer Center, University of Minnesota
Novartis Pharmaceuticals; Millennium Pharmaceuticals, Inc.

Terminated

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Pancreatic Cancer

United States
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
Yale University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Massey Cancer Center

Withdrawn

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Lymphoma | Relapsed and Refractory Aggressive B- and T-cell Lymphomas

United States
Novartis Pharmaceuticals

Completed

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (MACS1271)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple Myeloma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Celgene

Completed

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Melanoma | Lymphoma | Multiple Myeloma | Pancreatic Cancer | Non-Small Cell Lung Cancer

Australia
Stanford University

Terminated

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Cutaneous T-cell Lymphoma | Cutaneous Lymphoma

United States
Ohio State University Comprehensive Cancer Center
Novartis; Celgene

Completed

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States, Singapore
National Cancer Institute (NCI)

Completed

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (TARGET)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Stanford University
National Comprehensive Cancer Network

Completed

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis | Lung Cancer | Brain Cancer

United States
The Methodist Hospital Research Institute

Withdrawn

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (COMBOSTAT)

Non-Hodgkin Lymphoma
Mirati Therapeutics Inc.

Completed

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Myelodysplastic Syndrome

United States
Tiziana Marangon

Terminated

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

Multiple Myeloma

Italy
Mirati Therapeutics Inc.

Completed

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Urothelial Carcinoma

United States
Novartis Pharmaceuticals

Terminated

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (GEPARD)

Myelodysplastic Syndrome (MDS)

Germany
National Cancer Institute (NCI)

Terminated

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

Thymic Carcinoma | Thymoma

United States
National Cancer Institute (NCI)

Terminated

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC; Boston Children's Hospital; Brigham and Women's Hospital

Terminated

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Anemia

United States
National Cancer Institute (NCI)

Completed

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia... and other conditions

United States
National Cancer Institute (NCI)

Completed

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Sarcoma | Lymphoma | Neuroblastoma | WilmsTumor

United States

Search clinical trials for: Histone Deacetylase Inhibitors (HDACi)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations